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Phosphatidylserine (PS) membrane exposure plays an important role in blood coagulation, and the development of a liposome formulation
containing PS may be of potential therapeutic utility if they can be designed to achieve tumor selective thrombosis. The objective of this study
was to develop proof-of-principle data for a thrombogenic PS liposome targeted to vascular cell adhesion molecule 1 (VCAM-1) via the
attachment of an anti-VCAM-1 monoclonal antibody (Ab). We have evaluated binding of the anti-VCAM-1 Ab-conjugated PS liposomes to
VCAM-1 using two in vitro models, as well as assessing the ability of these liposomes to catalyze blood coagulation reactions. Binding of the
Ab-conjugated PS liposomes containing 2 or 14 mol% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene glycol) 2000]
(DSPE-PEG2000) to interleukin 1a stimulated human umbilical vein endothelial cells was 8- and 16-fold higher than those without conjugated
Ab, respectively, based on the percentage relative increase in cell associated lipid for these liposomes. Binding to VCAM-1-coated ELISA plates
produced similar results. The VCAM-1-bound Ab-conjugated PS liposomes were capable of catalyzing blood coagulation reactions upon the
exposure of the thrombogenic PS membrane surface. This control of PS surface exposure was achieved using exchangeable PEG-derivatized
phosphatidylethanolamines (PE-PEG), with 97% of clotting activity recovered after PE-PEG exchanged out. Our results demonstrate the
potential for considering further development of procoagulant liposomes that selectively target thrombogenesis in tumor vasculature.D 2003 Published by Elsevier B.V.Keywords: Liposome; Poly(ethylene glycol); Phosphatidylserine; Steric stabilization; Vascular cell adhesion molecule-1; Vascular targeting0005-2736/03/$ - see front matter D 2003 Published by Elsevier B.V.
doi:10.1016/S0005-2736(03)00142-1
Abbreviations: PEG, poly(ethylene glycol); PEG-lipids, poly(ethylene
glycol)-lipid conjugates; PE-PEG, poly(ethylene glycol)-derivatized
phosphatidylethanolamine; MPS, mononuclear phagocytic system; PS,
phosphatidylserine; DOPS, 1,2-dioleoyl-sn-glycero-3-[phospho-L-serine];
PC, phosphatidylcholine; SM, sphingomyelin; DSPC, 1,2-distearoyl-sn-
glycero-3-phosphocholine; DSPE-PEG2000, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamone-N-[poly(ethylene glycol) average MW 2000];
DSPE-PEG2000-MAL, poly(ethylene glycol)-a-distearoyl phosphatidyletha-
nolamine,-E-maleinmide; Chol, cholesterol; CHE, cholesterylhexadecyl
ether; POPE, 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphatidylethanol-
amine; BSA, bovine serum albumin; DTT, dithiothreitol; MAL, maleimide;
HUVEC, human umbilical vein endothelial cells; DIC, disseminated
intravascular coagulation; HBS, HEPES buffered saline; IL-1a, interleukin
1a; LUV, large unilamellar vesicles; MLV, multilamellar vesicles; PBS,
phosphate-buffered saline; SPDP, N-succinimidyl-3-(2-pyridyldithio) pro-
pionate; VCAM-1, vascular cell adhesion molecule 1
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There is growing interest in the treatment of solid tumors
based on vascular targeting agents that are designed to
selectively damage tumor vasculature. One approach to
achieve this goal has been to induce tumor selective throm-
bosis that leads to shutdown of the blood supply to tumor
cells [1,2]. This strategy has several advantages: (1) tumor
vascular endothelial cells are freely accessible to agents that
are injected intravenously; (2) tumor endothelial cells are
believed to be genetically stable and thus more predictable in
terms of response to therapy when compared to heteroge-
neous tumor cell populations; (3) occlusion of multiple
tumor vessels has the potential to produce an amplified
tumor cell killing effect since each tumor vessel feeds many
tumor cells; and (4) the strategy can be applied to different
solid tumor types since tumor blood vessels have similar
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well-known propensity of phosphatidylserine (PS) contain-
ing membranes to catalyze blood coagulation reactions [4],
the potential to develop a liposome-based vascular targeting
agent that contains PS for the induction of tumor selective
thrombosis is intriguing. In this regard, such PS-containing
liposome would likely have to exhibit unique attributes in
order to limit liposome recognition and thrombogenesis in
the central blood compartment while permitting binding and
the PS-mediated thrombogenesis once at the tumor site.
During the development of procoagulant PS-containing
liposomes, we have overcome several formulation chal-
lenges. First, we were able to protect and extend the
circulation longevity of PS-containing liposomes that would
otherwise be eliminated very rapidly by the mononuclear
phagocytic system (MPS). Although a surface density of 5
to 7 mol% PEG2000 is widely known to be an effective steric
barrier against plasma protein binding and cellular interac-
tions for neutral liposomes composed of PC, SM and Chol
[6,7], our findings demonstrated that >10 mol% DSPE-
PEG2000 is required to effectively protect PS-containing
liposomes from the high-affinity, PS-mediated plasma pro-
tein interactions that occur in circulation [5]. This protection
of the thrombogenic PS liposome surface is also required to
prevent disseminated intravascular coagulation. However, to
be of therapeutic value, the thrombogenic activity of PS
must be revealed following binding to an appropriate
vascular target. Once within the tumor vasculature, for
example, the well-protected PS liposome surface must
transform to one that is reactive toward the blood clotting
factors to trigger thrombosis. This transformation can be
controlled by selecting PEG modified lipids that desorb
from the liposomes, thus exposing the PS membrane sur-
face. In this regard, we have demonstrated that the mem-
brane surface reactivity of PS-containing liposomes toward
blood clotting factors can be controlled in a time-dependent
fashion by using exchangeable PEG-lipids of various acyl
chain lengths [8].
In the development of targeted thrombogenic liposomes
for tumor targeting, the PS-containing liposomes must also
selectively accumulate and localize within the tumor vas-
culature. Furthermore, this must be accomplished without
significantly altering the controlled surface exposure and
reactivity of the PS liposomes. One way to achieve this
selectivity is to exploit altered features of the vascular
endothelium within tumors. In solid tumors, the vasculature
is often marked by antigens that are overexpressed and/or
selectively expressed in the endothelial lining [9,10]. Vas-
cular cell adhesion molecule 1 (VCAM-1) is one such
antigen, and is present on the vascular endothelium of
several human malignant tumors including neuroblastoma
[11], renal carcinoma [12], non-small-cell lung carcinoma
[13], Hogkin’s disease [11], angiosarcoma [14] and colon
carcinoma [15]. In normal human tissues, a few vessels in
the thyroid, thymus and kidney display weak and patchy
VCAM-1 expression [14]. Thus, VCAM-1 would serve asan appropriate candidate for targeting thrombogenic PS
liposomes.
Before assessing the efficacy and toxicity of the VCAM-
1-targeted thrombogenic PS liposomes in animal models, it
was first necessary to demonstrate that these PS liposomes
would retain the surface reactivity toward the blood coag-
ulation proteins after binding to the desired target cell. The
in vitro studies presented here were undertaken to establish
that target bound thrombogenic PS liposomes remain func-
tional with respect to procoagulant activity. In this model
system, a monoclonal antibody (Ab) conjugated to the
thrombogenic PS liposomes was used for targeting the
liposomes to VCAM-1 expressing endothelial cells. Our
results contribute not only to the design of sophisticated,
multifunctional liposome carriers for targeted drug delivery,
but more importantly, to the development of potential lipid-
based therapeutics that target the tumor vasculature for
cancer therapy.2. Materials and methods
2.1. Materials
All lipids were purchased from Avanti Polar Lipids
(Alabaster, AL) except for DSPE-PEG2000-MAL, which
was from Shearwater Polymers Inc. (Huntsville, AL). The
[3H]CHE was obtained from NEN Life Sciences Products
(Oakville, ON, Canada). Cholesterol, DTT, ellagic acid and
Sephadex G-50 size exclusion gel were purchased from
Sigma. Recombinant human IL-1a was purchased from
R&D Systems. The hybridoma cell line VIII-6G10 (produ-
ces mouse IgG1 against human VCAM-1) was obtained from
the American Tissue Culture Collection (Manassas, VA), and
was sent to Antibody Solutions (Palo Alto, CA) for produc-
tion in bioreactors with purification. Mouse anti-human
VCAM-1 IgG1 (clone 1.G11B1), labeled with FITC, was
obtained from Calbiochem. Bio-Gel A 15-m size exclusion
gel was obtained from Bio-Rad (Mississauga, ON, Canada).
N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) was
purchased from Pierce.
2.2. Preparation of various liposomes
Large unilamellar vesicles were prepared according to
established procedures [16–18]. Lipids were dissolved in
chloroform and subsequently dried under a stream of nitro-
gen gas. The resulting lipid film was placed under high
vacuum for a minimum of 2 h, and was hydrated in HBS at
65 jC. The resulting preparation was frozen and thawed five
times prior to extrusion 10 times through stacked 0.1 Am
polycarbonate filters (Nucleopore Co., Canada) at 65 jC
with an extruder (Northern Lipids Inc., Vancouver, BC,
Canada). The resulting mean LUV diameter was 100–120
nm as determined by quasi-elastic light scattering using the
Nicomp submicron particle size model 370/270. MLV, used
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prepared with Egg PC/Chol (55:45 mole ratio), as described
elsewhere [8].
2.3. Conjugation of thiolated anti-VCAM-1 Ab to liposomes
The anti-VCAM-1 Ab and the irrelevant Ab (humanized
monoclonal Ab, HerceptinR, which contains a human
framework region with complimentary determining region
of a murine anti-p185 HER2 Ab that binds to HER2) were
conjugated to the liposomes according to established pro-
cedures [19,20]. The Ab was first modified with SPDP (1
nmol/Al) in a 1:5 mole ratio for 25 min at room temperature,
and was subsequently passed down a Sephadex G-50
column equilibrated with sodium acetate buffer (pH 4.5).
Fractions containing the Ab were pooled and were added to
DTT powder to give a final DTT concentration of 25 mM.
This mixture was incubated at room temperature for 25 min.
The thiolated Ab was then isolated by size exclusion
chromatography with a Sephadex G-50 column equilibrated
with HBS, and was immediately added to liposomes con-
taining 1 mol% DSPE-PEG2000-MAL (10 mM final lipid
concentration). The conjugation reaction was carried out at
room temperature for 18 h. The mixture was then passed
down a Bio-Gel A 15-m column equilibrated with HBS to
isolate the Ab-conjugated liposomes. The concentration of
the Ab-conjugated liposomes was determined by liquid
scintillation counting from aliquots mixed with 5.0 ml
Pico-fluor 15 scintillation fluid (Packard Biosciences, The
Netherlands), and counted with a Packard scintillation
counter model 1900 TR. The amount of Ab conjugated to
liposomes was determined using the Pierce Micro BCA
protein assay in the presence of 0.5% Triton X-100.
2.4. Liposome binding to surface bound VCAM-1
This assay was based on a previously described procedure
[21]. Briefly, recombinant human VCAM-1 (1 Ag/well, from
R&D Systems) was coated onto Maxisorp 96-well plate
(Nalge Nunc International, Rochester, NY) overnight at 4
jC in coating buffer (1.59 g Na2CO3/2.93 g NaHCO3 to 1 L,
pH 9.6). The plate was then blocked with 10% fetal bovine
serum for 1 h at 37 jC. Liposomes were then added to the
wells, and were incubated for 2 h at 37 jC. The wells were
washed three times with phosphate-buffered saline (PBS),
followed by the addition of 5% Triton X-100. After a 15-min
incubation at 37 jC, the content from each well was
transferred to a scintillation vial with three rinses of PBS,
and the radioactivity was determined by liquid scintillation
counting.
2.5. Induction and assessment of VCAM-1 expression on
human umbilical vein endothelial cells (HUVEC) by IL-1a
HUVEC were purchased from Clonetics, and were cul-
tured in EGM-2 medium supplemented with BulletKit (Clo-netics). Cells in the 3rd to 5th passages were used, and all
studies were completed with cells at f 70% confluence.
HUVEC were stimulated with 6.25 ng/ml IL-1a for 4 h at 37
jC. At the end of incubation, HUVEC were washed with
PBS/0.1% BSA twice, and were dislodged with PBS/2.5
mM EDTA for 5 min. Cells (2 105/sample) were pelleted
and resuspended in 0.1 ml PBS/10% human serum contain-
ing the FITC-labeled mouse anti-VCAM-1 Ab and incubated
on ice for 30 min. Cells were then washed twice with ice-
cold PBS/0.1% BSA, and resuspended in 0.4 ml ice-cold
PBS/0.1% BSA/propidium iodide for flow cytometry anal-
ysis using an EPICS Elite ESP flow cytometer (Beckman-
Coulter, Miami, FL) equipped with an Enterprise 621 laser
(Coherrent, Santa Clara, CA) set to measure fluorescence of
FITC. The flow cytometer scale was calibrated with Quan-
tum 24 or 25 beads (Flow Cytometry Standards, San Juan,
Puerto Rico), and 104 events were collected for each sample.
Data were analyzed with the ExpoMFA software. A previ-
ously described protocol was followed to quantify the
number of Ab binding sites, using Simply Cellular beads
(Flow Cytometry Standards) as a standard to determine the
fluorescence intensity per Ab [22].
2.6. Liposome binding to IL-1a stimulated HUVEC
HUVEC were stimulated with IL-1a as described above.
Subsequently, 1106 cells were placed in polypropylene
tubes, and [3H]CHE-labeled liposomes were added to
achieve a final liposomal lipid concentration of 2 mM.
Following an incubation at 4 jC for 4 h, the cells were
centrifuged at 300 g for 5 min, and washed three times
with PBS. Cells were solubilized with 0.9% Triton X-100 in
PBS, and the contents were transferred to a scintillation vial
for liquid scintillation counting.
2.7. In vitro clotting time assay
This assay was based on a procedure previously uti-
lized for assessing procoagulant activity of PS-containing
liposomes [5,8]. Briefly, Maxisorp Nunc-Immuno tubes
were coated with VCAM-1 (5 Ag/tube) as described in
Section 2.4 and pre-blocked with 10% serum. Liposomes
(250 nmol in 0.5 ml HBS) were added and incubated for 2
h at 37 jC. The tubes were then washed three times with
PBS. Human citrated plasma (125 Al), 10 5 M ellagic
acid (125 Al) and HBS (125 Al) were then added to the
tubes, which were then incubated for 2 min at 37 jC.
Calcium (8.75 mM, final concentration) was added to
initiate the clotting reaction, and the mixture (0.5 ml total)
was gently shaken. The time at which the mixture turned
into a viscous gel was recorded, and noted as the time
required for the clotting reaction to be completed. As indi-
cated, MLV were added to the tubes and incubated for 15
min, prior to the addition of the plasma mixture. The amount
of lipid bound to the tube was assayed as described
above.
Fig. 2. Binding of PS liposomes with or without Ab conjugation containing
2 mol% (white bar) or 14 mol% (gray bar) DSPE-PEG2000 to HUVEC at 4
jC for 4 h. HUVEC after stimulated with IL-1a were also blocked with free
anti-VCAM-1 Ab for 1 h before incubation with Ab-conjugated PS
liposomes containing 2 or 14 mol% DSPE-PEG2000. The percent relative
increase in cell associated lipid was calculated as follows: % relative
increase=(Lstim Lunstim)/Lunstim 100%, where Lstim represents the
amount of lipid per 106 cells for IL-1a stimulated HUVEC and Lunstim
represents the amount of lipid per 106 cells for unstimulated HUVEC. Two
independent experiments were done for each group with data points
representing averages. Evaluation of VCAM-1 expression on HUVEC by
flow cytometry post IL-1a stimulation at 37 jC for 4 h is shown as inset.
Dotted line, unstimulated HUVEC stained with IgG1-FITC; thin solid line,
unstimulated HUVEC stained with anti-VCAM-1-FITC; thick solid line,
stimulated HUVEC stained with anti-VCAM-1-FITC.
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3.1. Conjugation of anti-VCAM-1 Ab to PS-containing
liposomes
The anti-VCAM-1 Ab was conjugated to PS-containing
liposomes based on a well-established procedure [19,20].
The coupling efficiencies for PS liposomes containing 2
mol% DSPE-PEG2000 were between 55% and 61%, which
is comparable to other procedures that employed a thioether
linkage under similar reaction conditions [19,20,23,24].
Increasing the DSPE-PEG2000 level to 14 mol% decreased
the coupling efficiencies. When the initial Ab to lipid ratio
was 45 Ag Ab/Amol lipid, the coupling efficiency was 51%,
but when the initial ratio increased to 60 Ag Ab/Amol lipid,
the measured levels of coupled Ab did not increase and
therefore the efficiency of the reaction was less than 40%.
Reduced efficiency is possibly due to the decreased flexibil-
ity of the PEG spacer when elevated levels of DSPE-PEG2000
are present. An initial ratio of 45 Ag Ab/Amol lipid produced
similar final Ab to lipid ratios for PS liposomes containing 2
or 14 mol% DSPE-PEG2000 (23–27 Ag Ab/Amol lipid).
Based on these results, this ratio was used for subsequent
conjugation reactions to produce liposomes that had similar
Ab to lipid ratios for the evaluation of target binding.
3.2. Binding of anti-VCAM-1 Ab-conjugated PS liposomes
to target VCAM-1
Binding of the Ab-conjugated PS liposomes to VCAM-1
was first evaluated by an ELISA plate-based assay. BindingFig. 1. Binding of anti-VCAM-1 Ab-conjugated PS liposomes (squares),
irrelevant Ab-conjugated PS liposomes (triangles) and PS liposomes
without Ab (circles) containing 2 mol% (open symbols) or 14 mol% (solid
symbols) DSPE-PEG2000 to human VCAM-1 coated ELISA plates.
Liposomes (100 Al) at various concentrations were added to the ELISA
plates pre-blocked with 10% fetal bovine serum, and were incubated at 37
jC for 2 h. Data points represent the average of two experiments.trends were comparable for liposomes containing 2 or 14
mol% DSPE-PEG2000 with lipid concentrations up to 0.5
mM (Fig. 1). The amount of lipid recovered for the Ab-
conjugated PS liposomes with 2 mol% DSPE-PEG2000
reached maximum binding levels of 3.2 nmol per well,
representing a binding efficiency of f 1.6%. The amount
of binding for liposomes prepared with 14 mol% DSPE-
PEG2000 with added concentrations of >1 mM were less
than that observed for the formulation prepared with 2
mol% DSPE-PEG2000. The amounts of lipid recovered for
control Ab- and no Ab-conjugated PS liposomes with 2
mol% DSPE-PEG2000 at 2.0 mM lipid were 6- and 11-fold
lower than the value observed for anti-VCAM-1 Ab-conju-
gated PS liposomes. For those liposomes prepared with 14
mol% DSPE-PEG2000, the amount of lipid recovered was 9-
to 20-fold higher than the indicated controls. The in vitro
binding assay described above indicated that in a cell-free
system, specificity could be achieved for the anti-VCAM-1
Ab conjugated liposomes, and that nonspecific binding due
to the presence of PS was not substantially higher than that
observed for liposomes that lack PS.
The binding of liposomes to VCAM-1 was also evaluat-
ed using HUVEC stimulated with 6.25 ng/ml IL-1a (Fig. 2).
Flow cytometric analysis indicated that approximately 32%
of the HUVEC were stained positive with an FITC-labeled
anti-VCAM-1 Ab, and it was estimated that these cells have
Fig. 3. Clotting activity of Ab-conjugated PS liposomes post binding.
Various liposomes were allowed to bind to VCAM-1-coated ELISA tubes,
and the clotting activities were then assayed. The percent clotting activity
was calculated as follows:%=(tblank ttest)/(tblank tPS)100%,where t blank,
tPS and ttest represent the clotting times for HBS, 10% PS liposomes in
solution and test liposomes, respectively. The various liposomes (250 nmol
in 0.5 ml HBS) tested following addition to the VCAM-1 coated ELISA
tubes include: (1) PS 10%/PEG 2%/VCAM-1 Ab, (2) PS 10%/PEG 14%/
VCAM-1 Ab, (3) PS 10%/PEG 2%, (4) PS 10%/PEG 14%, (5) PS 10%,
all with DSPC/Chol as bulk lipids. All tubes were washed extensively
prior to addition of plasma. As controls, PS 10%/PEG 2%/VCAM-1 Ab
(6) and PS 10%/PEG 14%/VCAM-1 Ab (7) were added in same amounts to
the plasma to demonstrate the clotting activity of these liposomes free in
solution. Triplicates were done for each group, and the error bars represent
S.D. * denotes that the percentage clotting activities for (1) and (6) are
statistically different from the other groups ( P < 0.01), while (1) and (6) are
not statistically different from each other, as analyzed with one-way
ANOVA and Newman–Keuls test.
Fig. 4. Restoration of clotting activity upon the exchange of DMPE-PEG2000
out from the bound Ab-conjugated PS liposomes post binding. The
nonexchangeable DSPE-PEG2000 was included as a control. The test
conditions were described in Fig. 3 and the liposomes tested include: (1) PS
10%/DMPE-PEG 9%/VCAM-1 Ab +MLV incubation, (2) PS 10%/DMPE-
PEG 9%/VCAM-1 AbMLV incubation, (3) PS 10%/DMPE-PEG10%+
MLV incubation, (4) PS 10%/DSPE-PEG 14%/VCAM-1 Ab +MLV
incubation, (5) PS 10%/DSPE-PEG 14%/VCAM-1 AbMLV incubation,
(6) PS 10%/DSPE-PEG 15%+MLV incubation. All liposomes had DSPC/
Chol as bulk lipids. The MLV (as egg PC/Chol) were used as a sink to
capture the PEG-lipid that exchanged out of the PS liposomes, and were
added in 100-fold molar excess (0.6 Amol in 0.5 ml) HBS. Triplicates were
done for each liposome, with error bars representing S.D. * and ** denote
that (1) and (2) are statistically different from the other groups, respectively,
as analyzed with one-way ANOVA and Newman–Keuls test with P < 0.01.
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that efficient targeting to cells is obtained when the target
molecule is expressed in the range of 105–106 copies per
cell [25]. Although not all of the cells exhibited this level of
expression in this study, it can be argued that VCAM-1 is a
good target candidate for the thrombogenic PS liposomes
since localized thrombus formation within the tumor vas-
culature will not require binding to all endothelial cells.
Stimulated HUVEC were incubated with the pegylated
PS liposomes with or without conjugated anti-VCAM-1 Ab.
In the presence of the conjugated Ab, 4.8 and 4.2 nmol lipid
were associated with 1106 stimulated HUVEC for PS
liposomes containing 2 and 14 mol% DSPE-PEG2000,
respectively. By comparing binding to HUVEC that were
stimulated with IL-1a to those obtained with HUVEC that
were not exposed to IL-1a (no VCAM-1 expression), the
relative increases in cell-associated lipid for PS liposomes
containing 2 and 14 mol% DSPE-PEG2000 were calculated
to be 180% and 380%, respectively. The binding efficiency
of the anti-VCAM-1 Ab-conjugated PS liposome to IL-1a-
treated HUVEC was comparable to other studies, which
targeted liposomes to cell adhesion molecules such as
ICAM-1 and E-selectin [26–29]. Although the presenceof 14 mol% DSPE-PEG2000 compromised the coupling
efficiency of the Ab, this level of PEG-lipid did not
substantially interfere with the binding of the Ab-conjugat-
ed PS liposomes to VCAM-1. In fact, the data shown in
Fig. 2 suggest that the Ab-conjugated PS liposomes with 14
mol% DSPE-PEG2000 (gray bars) bound more efficiently
than the Ab-conjugated PS liposomes with 2 mol% DSPE-
PEG2000. To demonstrate the specificity of the Ab-con-
jugated pegylated PS liposome for the target VCAM-1,
IL-1a-treated HUVEC were pre-incubated with free anti-
VCAM-1 Ab prior to the addition of liposomes. Under
these conditions, binding values were reduced to those
observed with liposomes which did not have a conju-
gated Ab.
3.3. Assessment of the clotting activity of Ab-conjugated PS
liposomes post binding
In designing a thrombogenic PS liposome formulation
that is targeted to the tumor vasculature for triggering tumor
specific thrombosis, it is important for the PS liposomes to
maintain thrombogenicity after binding. We evaluated the
clotting activity of the bound Ab-conjugated PS liposomes in
ELISA tubes, where the lipid concentration used was one
that would result in maximum binding. As shown in Fig. 3,
all PS liposomes without Ab conjugation (Fig. 3, bars 3–5),
which exhibited negligible binding to the surface-bound
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to the fact that unbound liposomes were washed from the
tubes prior to initiating the coagulation reactions. The
amount of lipid recovered for Ab-conjugated PS liposomes
containing 2 and 14 mol% DSPE-PEG2000 were comparable,
which were 6.6 and 5.0 nmol per tube, respectively. When
these amounts of the specified liposomes were added directly
to the clotting assay (i.e., liposomes were not bound to a
surface), the clotting activities measured were comparable to
those measured with the bound liposomes (compare bars 1
and 2 to bars 6 and 7 in Fig. 3). Importantly, only the Ab-
conjugated PS liposomes containing 2 mol% DSPE-PEG2000
(Fig. 3, bar 1) exhibited clotting activity (80%) when bound
to the ELISA tubes. Tubes with bound Ab-conjugated PS
liposomes prepared with 14 mol% DSPE-PEG2000 (Fig. 3,
bar 2) gave < 10% clotting activity. These results are
consistent with our previous studies, which demonstrated
that elevated levels of a non-exchangeable PEG-lipid inhibits
PS clotting activity [5].
3.4. Controllable surface thrombogenicity of VCAM-1
bound PS liposomes using exchangeable PEG-lipids
We have utilized the exchangeable DMPE-PEG2000 to
demonstrate that loss of PEG from the PS liposomes is
crucial to the promotion of thrombi formation. The amount
of Ab conjugated to the DMPE-PEG 2000 containing PS
liposomes was 20 Ag Ab/Amol lipid, which was comparable
to that of DSPE-PEG2000 containing PS liposomes. The
clotting activities of the Ab-conjugated PS liposomes pre-
pared with maximum levels of PEG-lipid incorporation (9
mol% for DMPE-PEG2000 and 14 mol% for DSPE-
PEG2000) were measured after binding and incubation with
multilamellar vesicles (MLVs) to serve as a ‘‘sink’’ for the
PEG-lipids (Fig. 4) [8]. Both anti-VCAM-1 Ab-conjugated
PS liposomes containing 9 mol% DMPE-PEG2000 or 14
mol% DSPE-PEG2000 exhibited similar levels of bound
lipid following an incubation with the VCAM-1 coated
ELISA tubes, with 5.0 and 4.8 nmol lipid bound per tube,
respectively. The level of bound liposomal lipids was also
comparable under conditions where MLV were added,
indicating that MLV did not displace the Ab-conjugated
PS liposomes from the binding sites. The Ab-conjugated PS
liposomes protected by DMPE-PEG2000 recovered approx-
imately 97% clotting activity upon incubation with MLV
(Fig. 4, bar 1), compared to only 25% clotting activity
observed from those same liposomes but in the absence of
an MLV incubation (Fig. 4, bar 2). The Ab-conjugated PS
liposomes protected by the nonexchangeable DSPE-
PEG2000 exhibited < 10% clotting activity under the same
conditions regardless of whether the ELISA tubes were
incubated with or without MLV (Fig. 4, bars 4 and 5). This
clearly demonstrates that surface bound anti-VCAM-1 Ab-
conjugated PS liposomes can promote thrombus formation
and that this activity can be regulated through the use of
exchangeable PEG-lipids.4. Conclusion
The results of the in vitro studies presented here provide
proof-of-concept evidence that the VCAM-1 targeted throm-
bogenic PS liposomes maintain their surface reactivity
toward the blood coagulation factors, and that initiation of
coagulation activity can be controlled through the use of
exchangeable PEG-lipids. The ultimate therapeutic utility of
this liposomal formulation will depend on the ability to
selectively localize the triggered blood coagulation response
in tumor blood vessels without undesirable thrombosis in
healthy tissues. Given that cancer can induce an inflamma-
tory response with production of various cytokines, which in
turn, can induce VCAM-1 expression in vascular beds other
than that of the tumor, the specificity of anti-VCAM-1 Ab-
conjugated PS liposomes for the tumor vascular endothelium
will need to be carefully evaluated in relevant preclinical
models. We are currently establishing an appropriate tumor
bearing mouse model to evaluate the in vivo efficacy and
safety of these thrombogenic PS liposomes. In summary, our
in vitro results have demonstrated the functional require-
ments of a liposome-based PS formulation for the induction
of tumor selective thrombosis, and have provided supportive
evidence for continued development of such formulations for
therapeutic applications in vivo.Acknowledgements
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